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Characterized by dream-enactment motor manifestations arising from rapid eye movement (REM) 





comparisons). All data were extracted from the Parkinson’s Progression Markers Initiative. PD patients 
with probable RBD showed smaller volumes than patients without RBD and than healthy controls in the 
pontomesencephalic tegmentum, medullary reticular formation, hypothalamus, thalamus, putamen, 
amygdala and anterior cingulate cortex. These results demonstrate that RBD is associated with a 
prominent loss of volume in the pontomesencephalic tegmentum, where cholinergic, GABAergic and 
glutamatergic neurons are located and implicated in the promotion of REM sleep and muscle atonia. It 
is additionally associated with more widespread atrophy in other subcortical and cortical regions whose 
loss also likely contributes to the altered regulation of sleep-wake states and motor activity underlying 
RBD in PD patients.
RBD is characterized by episodes of dream-enactment behaviors, during which abnormal motor activity during 
REM sleep often results in dramatic movements such as punching, flailing or jumping out of the bed1. It has been 
suggested that RBD results from an alteration of brainstem neural systems controlling motor inhibition during 
REM sleep2,3. Lesions in the brainstem, particularly involving the mesencephalic, pontine or medullary reticular 
formation (RF), were originally shown in animal models to produce REM sleep without atonia and acting out 
dreams4–7. In humans, neuropathological studies of small series of RBD patients have revealed loss of neurons in 
the region of the pontomesencephalic tegmentum (PMT)8. To generalize these findings, neuroimaging studies 
have compared regional brain volumes between subjects with idiopathic RBD (i.e., in the absence of any other 
neurological disorder) and subjects without. Studies of 12 to 26 idiopathic RBD patients demonstrated subtle 
structural alterations (indexed by MRI diffusion parameters) in regions compatible with the PMT and RF9,10, and 
the presence of altered regional brain volumes in these areas was reported in one study11 but not in two others9,12, 
which questions the consistency of pontine neuronal loss in idiopathic RBD.
Beyond these studies of ‘idiopathic’ RBD, recent studies have focused on RBD in presence of neurodegen-
erative disorders. Indeed, there is increasing evidence that RBD is associated with α -synucleinopathies such as 
PD, dementia with Lewy bodies and multiple system atrophy. The prevalence of RBD in the general population 
is approximately 0.5%,13 while this prevalence increases noticeably in PD (37 to 47%)14–16. In fact, RBD is consid-
ered as an early symptom of α -synucleinopathies17. Yet not all patients with these syndromes are affected by RBD. 
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Besides the occurrence of dream-enactment behaviours, PD patients with RBD show differences in their clinical 
characteristics compared to those without, such as more severe cognitive and motor impairments, higher sleep-
iness levels and more frequent hallucinations18. It remains unclear whether these differences are subtended by 
specific brain anatomical changes. Indeed, few neuroimaging studies have investigated alterations associated with 
RBD in PD patients. An MRI study of 24 PD patients with RBD compared to 12 patients without showed subtle 
structural alterations in the PMT reflected by a decrease of neuromelanin-sensitive signal in the locus coeruleus/
subcoeruleus within the PMT19. However, no significant change in regional brain volume was observed between 
the two PD groups in that study when using voxel-based morphometry (VBM).
Therefore evidence in RBD patients for extensive neurostructural alterations encompassing systems 
regulating REM sleep atonia remains to be clearly established. Most neuroimaging studies of RBD used a 
video-polysomnography assessment to provide a comprehensive diagnostic confirmation of RBD. This approach, 
while favoring a high internal validity, usually precludes the inclusion of large samples of participants. Yet 
resorting to larger cohorts of RBD patients – screened with validated questionnaires – might constitute a useful 
approach to demonstrate consistent patterns of structural brain changes associated with this condition. In the 
present study, we characterized brain abnormalities associated with the presence of RBD in a large population of 
PD patients. We used deformation-based morphometry (DBM) analyses on T1-weighted MRI images to iden-
tify significant differences in regional brain volumes between PD patients with probable RBD (pRBD) and PD 
patients without RBD (noRBD), based on the RBD screening questionnaire (RBDSQ)20. DBM allows a detection 
of volume differences in both grey and white matter, and was found more sensitive than conventional VBM 
methods in detecting volume changes in early-stage PD patients21. All data were extracted from the database of 
the Parkinson’s Progression Markers Initiative (PPMI), a multicenter program aimed at identifying progression 
biomarkers in newly diagnosed PD patients22.
Results
Clinical and imaging data of 69 pRBD, 240 noRBD and 138 healthy controls (HC) were obtained from the PPMI. 
Clinical data of the three groups were compared and are illustrated in table 1. There was no significant difference 
in demographic characteristics (age, sex and level of education) between the three groups. However, in the case 
of family history of PD, the two patient groups had a higher incidence of PD in their families compared to con-
trols. Also, per the inclusion criteria, the two patient groups were all newly diagnosed with PD (≤2 years) and 









 Age# 60.93 ± 9.16 61.62 ± 9.84 59.92 ± 10.83
 Sex (M:F)§ 52:17 149:91 90:48
 Education (Years)# 15.86 ± 2.34 15.63 ± 2.90 16.28 ± 2.92
 Parkinson’s Disease Duration since Diagnosis (Months)† 6.29 ± 6.62 6.85 ± 6.66 N/A
 Family History of Parkinson’s Disease§ 30.4%c 23.3%c 5.1%a,b
 RBDSQ Score# 8.12 ± 1.97b,c 2.45 ± 1.15a,c 1.93 ± 1.33a,b
Parkinson’s disease rating scales 
 UPDRS I# 7.91 ± 4.44b,c 4.88 ± 3.57a,c 2.76 ± 3.18a,b
 UPDRS II# 8.41 ± 5.30b,c 5.38 ± 3.91a,c 0.38 ± 0.92a,b
 UPDRS III# 22.45 ± 9.46c 21.14 ± 8.83c 1.03 ± 2.13a,b
 SE-ADL† 91.96 ± 5.77b 93.92 ± 6.10a N/A
Other clinical scales#:
 Epworth Sleepiness Scale 6.94 ± 4.66b,c 5.50 ± 3.29a 5.25 ± 3.46a
 University of Pennsylvania Smell Identification Test 20.67 ± 8.67b,c 22.66 ± 8.14a,c 34.30 ± 4.00a,b
 Geriatric Depression Scale 3.04 ± 2.45b,c 2.00 ± 2.24a,c 1.39 ± 2.41a,b
 State-Trait Anxiety Inventory - State 38.19 ± 9.00b,c 34.50 ± 7.43a,c 31.82 ± 6.37a,b
 State-Trait Anxiety Inventory - Trait 35.16 ± 10.19b,c 31.38 ± 9.12a,c 28.72 ± 7.79a,b
 Montreal Cognitive Assessment 27.77 ± 2.63 28.16 ± 2.36 28.20 ± 1.11
 Symbol Digit Modalities Test 40.04 ± 10.28c 42.22 ± 9.71c 46.80 ± 10.18a,b
 Semantic Verbal Fluency Test (Scaled Score) 10.19 ± 2.78b,c 11.05 ± 2.97a 11.19 ± 2.88a
 Visuospatial skills (Benton’s Judgment of Line Orientation) 12.22 ± 2.34b,c 12.94 ± 1.94a 13.11 ± 2.10a
 SCOPA-Autonomic 12.30 ± 6.51b,c 8.22 ± 5.28a,c 5.33 ± 3.66a,b
Table 1. Clinical characteristics. Means ± standard deviations are presented and statistically compared. 
Statistical differences, with significance at P < 0.05, are indicated between groups by corresponding letters; 
aParkinson’s disease patients with probable RBD, bParkinson’s disease patients without RBD and chealthy 
controls. #Based on Post-hoc Bonferroni pairwise. †Based on Student t test. §Based on Pearson’s χ2 test. 
Abbreviations: F: Female, M: Male, N: Number of subjects, RBDSQ: Rapid eye movement sleep behaviour 
disorder screening questionnaire, SCOPA: Scales for outcomes in Parkinson’s disease, SE-ADL: Modified 
Schwab and England activities of daily living scale, UPDRS: Unified Parkinson’s disease rating scale.
www.nature.com/scientificreports/
3Scientific RepoRts | 6:26782 | DOI: 10.1038/srep26782
scales in Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) I and II than 
noRBD. They also showed more severe daytime sleepiness using Epworth Sleepiness Scale (ESS), olfactory deficit 
using University of Pennsylvania Smell Identification Test (UPSIT), depression and anxiety scores. Finally, pRBD 
showed lower cognitive performance than noRBD at the Symbol Digit Modalities Test (SDMT), Semantic Verbal 
Fluency Test (SVFT) and Benton’s Judgment of Line Orientation (BJLO), as well as more pronounced autonomic 
dysfunction.
To evidence abnormalities associated with the probable presence of RBD in PD, a DBM comparison between 
the two PD groups was made (Table 2). At the level of the brainstem (Fig. 1), a smaller volume was observed in 
pRBD compared to noRBD in a region encompassing the PMT, including the oral pontine RF, the pedunculopon-
tine tegmental nucleus (PPT), the laterodorsal and sublaterodorsal tegmental nuclei (LDT, SubLDT) and the ven-
tral periaqueductal gray matter (PAG) along with the raphe nuclei. The region of smaller volume extended rostrally 
into the dorsal mesencephalic tegmentum including areas compatible with the mesencephalic RF and the PAG. It 
also extended caudally to affect areas compatible with the caudal pontine RF, the locus coeruleus/subcoeruleus, 
and the base of the pons. At the level of the medulla, smaller volume mainly affected the region of the medullary 
RF. In the forebrain (Fig. 2), a significantly smaller volume was observed in pRBD in the hypothalamus, thalamus, 
putamen, and amygdala. At the cortical level, smaller grey matter volumes included the anterior cingulate cortex. 
Besides these smaller volumes, patients with pRBD showed a larger volume of grey matter in several regions, 
including the olfactory trigone, medial prefrontal cortex, superior and inferior frontal gyri (Fig. 2, Table 2).
When focusing the analysis on the PMT area only, the pRBD showed a significantly smaller relative PMT 
volume compared to noRBD (p = 0.003) (Supp. Fig. 1B).
To further evaluate whether these structural modifications were more specifically linked to the presence of 
RBD rather than PD itself, neuroimaging data of the two PD groups were respectively compared to HC (Fig. 3, 
Supp. Table 1). As expected, the vast majority of structural modifications associated with pRBD compared to 
noRBD were also observed in pRBD compared to HC, with the notable exception of the lower volume in the 
substantia nigra. The latter was found in both pRBD compared to HC and noRBD compared to HC (Fig. 3), but 
not in the comparison between the two PD groups (Figs1 and 2).
The correlation analyses did not reveal any significant association between relative volume differences in the 
predefined regions of interest (see methods section) and their corresponding clinical characteristics.
Finally, a smaller subsample of controls without PD met the RBDSQ criteria for probable idiopathic RBD 
(piRBD, n = 17) and were thus considered in the supplementary analyses where they were compared to a matched 
subpopulation of HC (n = 17, see supplementary data). This analysis showed several volume differences, includ-
ing a lower volume in the PMT with piRBD (Supp. Table 2, Supp. Fig. 2).
Discussion
Using DBM on a large sample of PD patients, we demonstrated extensive subcortical and cortical structural 
abnormalities associated with RBD in PD, whereas two previous neuroimaging studies on PD patients with RBD 
demonstrated only subtle (pontine) structural alterations but no statistically significant difference in regional 
brain volumes19,23. At the subcortical level, we found that pRBD patients manifest distinctly smaller volumes 
in the brainstem (PMT and medullary RF), cerebellum, diencephalon (hypothalamus and thalamus), striatum 
(putamen), and limbic system (amygdala). At the cortical level, they manifest distinct patterns of both smaller 
(anterior cingulate) and larger (olfactory) grey matter volumes. No significant volume difference was observed in 
the substantia nigra between the two PD groups, whereas this structure showed significantly smaller volume in 
pRBD and noRBD compared to HC, indicating that changes in the substantia nigra were specifically linked to PD.
At the level of the brainstem, smaller volumes in pRBD were mainly localized in a large cluster within the 
PMT in PD patients. A smaller volume in a more restricted region of the PMT was also found when comparing 
piRBD and HC. A few published case reports have described the occurrence of RBD symptoms with lesions 
encompassing the pontine tegmentum2,24, which offered early indications that alterations in this region might be 
involved in the loss of REM muscle atonia. Neuroimaging studies of idiopathic RBD evaluated the presence of 
structural alterations of this region in the absence of macroscopic lesions9–12. A relative lack of consistency in the 
results precluded a firm conclusion since only one of these studies demonstrated smaller volume in the pontine 
tegmentum11, two others showed only subtle structural changes in this region on MRI diffusion sequences9,10, and 
another one reported no volume change in this area12. In addition, previous neuroimaging studies of RBD in the 
presence of PD did not demonstrate any significant volume change of the PMT19,23,25. The present finding on 69 
PD patients with probable RBD thus constitutes the first evidence for a significant PMT volume loss in PD with 
RBD, and thus demonstrates the key importance of PMT alteration in the loss of REM atonia underlying RBD. 
Further caudally in the brainstem, volume decrease also involved the medullary RF, which is known to be part of 
the neuronal system promoting muscle atonia during REM sleep3,26. Animal studies and a human case report have 
shown that lesions in the medullary RF are associated with loss of REM muscle atonia and RBD5,27. Collectively, 
the changes observed through the brainstem indicate that RBD involves degeneration of broadly distributed 
neural populations. These could include cholinergic neurons of the PMT (PPT, LDT and SubLDT), which have 
been shown to promote REM sleep with muscle atonia7,28, and for which evidence of loss has been reported in 
imaging studies of PD with RBD29. More numerous glutamatergic neurons are also present in this region and 
implicated in the control of muscle atonia3,28,30. GABAergic neurons are also present in the PMT and include neu-
rons that are maximally active during REM sleep and can inhibit other neurons, including noradrenergic neurons 
of the locus coeruleus and serotonergic neurons of the raphe, which promote arousal with muscle tone26,28. Here, 
a smaller volume was found in pRBD in regions encompassing the locus coeruleus/subcoeruleus and raphe, 
in line with a previous MRI study19. Such results indicate that there are distributed neuroanatomical/chemical 
alterations affecting multiple cell populations to differing degrees, some of which normally play opposing roles 
in the occurrence of REM sleep and muscle atonia. The symptoms of RBD thus likely result from imbalances 
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Area Xa Ya Za T-scoreb P-valuec
pRBD < noRBD
Pontomesencephalic Tegmentum
 Left − 4 − 28 − 22 − 3.70 0.00011
 Right 4 − 30 − 20 − 2.72 0.00312
Base of the Pons
 Left − 5 − 18 − 36 − 3.50 0.00029
 Right 4 − 18 − 34 − 2.72 0.00291
Medullary Reticular Formation
 Left − 4 − 42 − 62 − 2.71 0.00364
Cerebellum – Deep Nuclei
 Left − 24 − 46 − 34 − 3.60 0.00022
 Right 24 − 46 − 34 − 3.90 0.00006
Cerebral Peduncle 
 Left − 12 − 18 − 20 − 2.72 0.00376
 Right 12 − 16 − 18 − 2.33 0.01107
Hypothalamus
 Left − 4 − 4 − 10 − 3.31 0.00056
 Right 4 − 6 − 10 − 4.29 0.00001
Thalamus
 Left − 19 − 18 16 − 3.31 0.00059
 Right 12 − 20 0 − 3.50 0.00025
Putamen
 Left − 24 10 − 10 − 4.19 0.00002
 Right 32 − 6 − 6 − 3.31 0.00062
Claustrum
 Left − 29 12 − 8 − 3.50 0.00025
 Right 32 10 − 8 − 3.99 0.00004
Internal Capsule – Posterior lobe
 Left − 22 − 12 10 − 3.11 0.00125
 Right 24 − 18 10 − 2.91 0.00210
Amygdala
 Left − 26 − 8 − 12 − 3.50 0.00023
 Right 30 − 8 − 8 − 3.21 0.00069
Lingual Gyrus 
 Left − 22 − 68 − 15 − 3.21 0.00084
 Right 32 − 70 − 10 − 2.91 0.00150
Supramarginal Gyrus
 Left − 56 − 32 32 − 3.21 0.00090
Anterior cingulate
 Right 14 50 − 12 − 3.21 0.00077
Superior Longitudinal Fasciculus
 Left − 22 − 12 32 − 3.51 0.00025
 Right 22 8 32 − 3.50 0.00034
Inferior Longitudinal Fasciculus
 Left − 36 − 4 − 24 − 3.99 0.00004
 Right 34 2 − 20 − 3.90 0.00006
pRBD > noRBD
Olfactory Trigone
 Left − 6 18 − 23 2.58 0.00451
 Right 6 12 − 18 3.66 0.00019
Rectal Gyrus/Orbitofrontal Gyrus
 Right 10 36 − 14 3.96 0.00003
Medial Prefrontal Cortex
 Left − 4 54 36 3.27 0.00064
 Right 6 54 38 4.25 0.00001
Continued
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due to alterations in these diverse sleep-wake executive and regulatory neurochemical systems5,7,28. Although 
these observed changes in brain volume might in theory reflect losses in both neuronal and non-neuronal tissues 
(e.g., glial cells), evidences of neuronal degeneration (e.g., cholinergic, dopaminergic) were previously shown in 
PD with RBD and idiopathic RBD patients29,31.
In the forebrain, reduced volume with pRBD was observed in the thalamus – in agreement with a previous 
MRI study25 – as well as in the hypothalamus, which might be partly responsible for the increased sleepiness lev-
els of these patients32. Moreover, orexin neurons, which play a critical role in maintenance of arousal and muscle 
tone33, are located in the hypothalamic region where volume reduction was seen here. Loss of orexin neurons, 
which has been shown to occur with PD34, could thus be associated with increased sleepiness in RBD patients, but 
also with the reported appearance in some RBD patients of narcolepsy with cataplexy35. Other volume decreases 
affected structures involved in motor control, such as the cerebellum and putamen, in line with previous MRI 
studies in idiopathic RBD11,36. Smaller volumes in these regions may reflect the decreased striatal dopaminer-
gic innervation31, as well as the more severe motor impairments37 observed in patients with RBD. The smaller 
volumes in the limbic system (amygdala, anterior cingulate) might contribute to the changes in mood scores 
observed in pRBD, in line with the greater depression levels previously reported in this population15. At the corti-
cal level, pRBD showed larger grey matter volumes including areas that belong and surround the olfactory cortex 
such as the olfactory trigone, the gyrus rectus and the orbitofrontal cortex. Previous MRI studies also showed 
Area Xa Ya Za T-scoreb P-valuec
pRBD > noRBD
Superior Frontal Gyrus
 Left − 6 14 50 2.98 0.00165
 Right 5 20 58 3.86 0.00008
Inferior Frontal Gyrus
 Left − 51 16 16 3.37 0.00039
 Right 56 26 16 3.76 0.00009
Mid-Cingulate Gyrus
 Left − 16 − 24 40 3.76 0.00009
 Right 12 − 18 40 4.06 0.00003
Superior Temporal Gyrus
 Left − 64 − 48 20 4.16 0.00002
 Right 69 − 42 16 4.65 0.00000
Table 2.  Areas of significant volume difference in PD patients with probable RBD (pRBD) compared to 
PD patients without (noRBD). aBased on Montreal Neurological Institute 152 brain imaging template; bPeak 
voxel T-score; cPeak voxel P-value.
Figure 1. Volume change comparison between PD patients with (pRBD) and without (noRBD) probable 
RBD in the brainstem. Thresholded t maps (at P < 0.05 corrected for multiple comparisons) superimposed 
onto Montreal Neurological Institute 152 brain imaging template (i.e., a normalized average of 152 3D T1-
weighted MRI scans from a normative adult population). The color-coded bar represents t values and the 
display is thresholded at P < 0.05. Left, sagittal plane showing smaller volume in the pontomesencephalic 
tegmentum (PMT) (arrow), the ventral medulla (arrow head), and base of pons (dashed arrow). Right, coronal 
plane showing the bilateral smaller volume in the PMT area (arrow).
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structural changes in the olfactory cortex of idiopathic RBD patients10,12. Olfactory deficits have been reported 
in idiopathic RBD patients38 as well as in PD patients39. In the present dataset, olfactory deficits were found more 
pronounced in pRBD compared to the other groups. Therefore, the larger volume reported might represent a 
compensatory phenomenon to the more severe clinical olfactory deficits observed in pRBD.
Finally, since polysomnography data were not available in the PPMI dataset at the time of this analysis, they 
could not be used to confirm the definitive diagnosis of RBD. While this is a limitation of the current study, 
RBDSQ scores used to identify RBD were shown to have high sensitivity (96%) and specificity (85%)20 and were 
Figure 2. Volume change comparison between PD patients with (pRBD) and without (noRBD) probable 
RBD in sub-cortical and cortical areas. Thresholded t maps (at P < 0.05 corrected for multiple comparisons) 
superimposed onto Montreal Neurological Institute 152 brain imaging template. The color-coded bar represents t 
values and the display is thresholded at P < 0.05. (A) Areas of significantly smaller volume in pRBD. Upper level: 
Left, sagittal plane showing smaller volumes in the thalamus (arrow) and the anterior cingulate (arrow head). 
Middle, coronal plane showing smaller volumes in the putamen (arrow) and the claustrum (arrow head). Right, 
axial plane showing smaller volume in the posterior limb of the internal capsule (arrow). Lower level: Left, sagittal 
plane showing smaller volumes in the lingual gyrus (arrow) and the cerebellum (arrow head). Middle, coronal 
plane showing smaller volumes in the amygdala (arrow) and the hypothalamus (arrow head). Right, axial plane 
showing smaller volumes in the middle and anterior part of the superior longitudinal fasciculus (arrow), and the 
supramarginal gyrus (arrow head). (B) Areas of significantly larger volume in pRBD. Left, sagittal plane showing 
larger volume in an area encompassing the rectal gyrus and the orbitofrontal gyrus (arrow), the olfactory trigone 
(arrow head), and the medial prefrontal cortex (dashed arrow). Middle, coronal plane showing larger volume in 
the superior frontal gyrus (arrow) and the inferior frontal gyrus (arrow head). Right, axial plane showing larger 
volume in the mid-cingulate gyrus (arrow).
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validated across several studies and population samples, including PD patients40–43. In addition, validated RBD 
questionnaires have been increasingly used in recent studies, in which RBDSQ-based probable RBD was associ-
ated with other clinical markers of neurodegeneration, illustrating the relevance of such questionnaires in studies 
with large sample sizes44.
In the present study, no significant correlation was observed between volume changes in specific regions of 
interest and selected clinical parameters, such as RBDSQ, self-reported mood scales or cognitive measures. This 
suggests that clinical differences associated with RBD in PD might not result from the impairment of specific 
brain structures considered separately, but rather from the alteration and resulting imbalance in complex sys-
tems and neural networks regulating sleep-wake cycles, sensorimotor control, as well emotional and cognitive 
processes.
Figure 3. Volume change comparison between PD patients with (pRBD) and without (noRBD) probable 
RBD and healthy controls (HC). Thresholded t maps (at P < 0.05 corrected for multiple comparisons) 
superimposed onto Montreal Neurological Institute 152 brain imaging template. The color-coded bar represents 
t values and the display is thresholded at P < 0.05. (A) DBM group comparison between pRBD and HC showing 
areas of significantly smaller volume in pRBD in sub-cortical and cortical regions. Top, sagittal plane showing 
smaller volumes in the PMT (arrow), the ventral medulla (arrow head) and the anterior cingulate (dashed arrow). 
Middle, coronal plane showing smaller volumes in the substantia nigra (arrow), the hippocampus (arrow head) 
and the thalamus (dashed arrow). Bottom, axial plane showing smaller volumes in the putamen (arrow), the 
hypothalamus (arrow head) and the lingual gyrus (dashed arrow). (B) DBM group comparison between noRBD 
and HC showing areas of significantly smaller volume in noRBD, encompassing the substantia nigra (arrows).
www.nature.com/scientificreports/
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Conclusions
Resorting to brain morphometric analyses with DBM in a large cohort of PD patients, the present study revealed 
extensive structural abnormalities associated with RBD. These changes prominently involved volume decreases in 
the PMT, providing strong support for a consistent loss of neurons in this region with RBD, and thus emphasizing 
the key role of PMT in the control of muscle atonia during human REM sleep. Beyond the PMT, our results show 
for the first time the presence of distributed cortical and subcortical structural modifications associated with 
the presence of RBD in PD. This complex collection of neuroanatomical changes might contribute to the altered 
regulation of sleep-wake states and motor activity underlying RBD, as well as to the more severe clinical deficits in 
non-motor domains (e.g., olfaction, sleepiness, cognition) that characterize PD patients with RBD.
Materials and Methods
Subjects. All MRI and clinical data were extracted from the PPMI database: http://www.ppmi-info.org/ 22. 
The data from this database are openly accessible through a standard application process. The PPMI program 
was approved by the Institutional Review Board of each participating site. All participants to the PPMI gave their 
written informed consent to participate to the program. In accordance with PPMI policies, our manuscript was 
reviewed by the PPMI Data and Publications Committee for administrative approval. The analyses presented in 
this article were thus carried out in accordance with the approved PPMI guidelines.
PD patients in the PPMI cohort were diagnosed within the last two years, and were all drug naïve. Given the 
absence of polysomnography in the current PPMI database, the probable presence or absence of RBD in PD 
patients was based on RBDSQ. This 10-item structured questionnaire, which centres on the characteristics of 
dreams and dream enactment behaviours, has been validated as a screening tool for RBD20,40–43. A RBDSQ score 
≥ 5 demonstrated a sensitivity of 96% and specificity of 56% for RBD detection20. In addition, single-item analysis 
revealed that each of three specific questions from RBDSQ (items 5, 6.3 and 6.4) had specificity above 85% for 
RBD diagnosis. Here, to ensure optimal sensitivity (96%) and specificity (>85%) of classification, PD patients 
combining both RBDSQ score ≥ 5 and positive response to item 5, 6.3 or 6.4 were considered as probable RBD 
(pRBD; n = 69). PD patients presenting a RBD score <5 were considered as without RBD (noRBD; n = 240). 
We extracted the data of subjects who completed the MRI scanning and the RBDSQ. For subjects with repeated 
RBDSQ assessments, we selected the RBDSQ that was the closest to the MRI scanning day. Control subjects with-
out PD (i.e., had no history of PD in their first-degree blood relative) were also available in the PPMI database 
and were added to the comparison. Using the same RBDSQ criteria mentioned above, controls were classified as 
without RBD (healthy controls, HC) or with probable RBD (probable idiopathic RBD, piRBD). The main analy-
sis aimed at comparing the two groups of PD patients (pRBD and noRBD), to identify structural abnormalities 
associated with probable RBD. To further differentiate structural abnormalities associated with RBD from those 
related to PD, secondary analyses were made to compare pRBD and noRBD groups to HC (n = 138) respectively. 
Finally, supplementary analyses compared piRBD and HC (Supp. Table 2 and Fig. 2)
Clinical characteristics. We compared clinical scores between pRBD, noRBD and HC to provide insight 
into the significance of structural brain differences. To evaluate the severity of PD symptoms, (MDS-UPDRS) I, 
II and III as well as Modified Schwab and SE-ADL were used. Neuropsychiatric scales included the ESS, Geriatric 
Depression Scale (GDS), State-Trait Anxiety Inventory (STAI) and UPSIT. Cognitive assessments included 
the Montreal Cognitive Assessment (MoCA), SVFT, SDMT and BJLO. Scales for Outcomes in PD-Autonomic 
(SCOPA-AUT) was used to evaluate autonomic dysfunctions. One-way analyses of variance followed by 
Bonferroni post-hoc comparisons (for continuous variables), and Chi-square tests (for categorical variables) were 
performed in SPSS (version 21) to reveal significant differences in these parameters between the three groups 
(p < 0.05; Table 1).
MRI acquisition. Non-contrast enhanced 3D volumetric T1-weighted brain MRI scans were acquired using 
1.5 or 3 Tesla scanners. A majority of subjects were scanned using a 3 Tesla MR scanner: out of 69 pRBD, 26 were 
scanned with 1.5 Tesla MR scanner and 43 with a 3 Tesla; out of 240 noRBD, 73 were scanned at 1.5 Tesla and 
167 at 3 Tesla; out of 138 HC, 45 were scanned at 1.5 Tesla and 93 at 3 Tesla. There was no significant difference 
in the proportion of subjects scanned at 1.5 Tesla vs 3 Tesla across the three groups (Chi square test, p = 0.520). 
To minimize bias in data between sites, the PPMI core optimized the acquisition sequence across sites to maxi-
mize comparability of data in the study. Typical MRI parameters were as follows: repetition time 5–11 ms; echo 
time 2–6 ms; slice thickness 1–1.5 mm; inter slice gap 0 mm; voxel size 1* 1* 1.2 mm; matrix 256 * minimum 160. 
Details can be found at http://www.ppmi-info.org/wp-content/uploads/2010/07/Imaging-Manual.pdf.
MRI analysis. The MINC software (MINC Tool Kit, Montreal Neurological Institute, McGill University, 
Montreal, Canada) was used for data analysis and images generation. Quality control of the images was manually 
verified for each step of processing. If necessary, data was manually initialized (e.g., registration). Pre-processing 
steps were applied prior to estimating the deformations: (1) N3 non-uniformity correction; (2) linear normaliza-
tion of individual scan’s intensity range to (0–100) by a single linear histogram scaling; (3) automatic linear (nine 
parameters) registration to the ICBM 152 stereotaxic space; and (4) brain mask creation. Only voxels within the 
brain volume after linear mapping into stereotaxic space were used for nonlinear registration. Using nonlinear 
transformations, voxel-wise deformations were calculated to make inferences about regionally specific differences 
between populations. A robust automated processing pipeline was used to control the bias due to multisite MRI 
scanning (i.e., magnetic field strength) and has been successfully applied to a number of multi-site collaborative 
projects45–49. Moreover, to further account for these multisite-related differences, magnetic field strength was also 
controlled along with age and gender in all parametric statistical tests.
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DBM was used to compare brain morphometric changes between groups50. In brief, the local volume dif-
ference at each voxel was computed and used to measure possible brain tissue growth or loss. To compare brain 
volumetric changes between groups, independent voxel-by-voxel t-tests were used and results were thresholded at 
P value < 0.05 after correction for multiple comparisons using the false discovery rate (FDR). To avoid reporting 
insignificant volume changes, only clusters with ≥ 50 contiguous voxels were considered51,52.
Mean volume changes of the PMT area were additionally calculated and compared (independent t-test) 
between pRBD and noRBD (p < 0.05). The PMT was manually defined on the Montreal Neurological Institute 
152 nonlinear 2009 ICBM template and the integral of the determinant of the Jacobian of the individual’s esti-
mated deformation field was computed within this mask (Supp. Fig. 1A).
Finally, to assess whether differences in clinical characteristics between PD patients with and without RBD 
might be associated with regional brain volume changes, correlation analyses between volume changes and clini-
cal variables were performed across the two patients groups using Pearson’s linear correlations (corrected for age, 
PD duration since diagnosis, and MRI scan parameters; p < 0.05). We restricted our correlations to the regions 
most consistently reported in neuroimaging studies of idiopathic RBD9,12,36,53. The following correlations were 
thus performed: the volume change in the PMT and the RBDSQ score; the olfactory trigone and the UPSIT; the 
putamen and the MDS-UPDRS III; the anterior cingulate cortex and the GDS; the medial prefrontal cortex and 
cognitive tests (MOCA, SDMT, SVF). These regions of interest were manually defined on the ICBM template and 
the relative volume estimated as described above. The level of significance was set at p < 0.05.
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